Dishman Seeks $25 Million For Newly Open China Production Facility
This article was originally published in PharmAsia News
Executive Summary
Dishman Pharmaceuticals and Chemicals is offering its plant in China for sale even as it begins production of intermediates after years of regulatory delays.
You may also be interested in...
Seretide Settlement To Lift Glenmark’s Europe Business
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
US/India Operation Intercepts Unapproved Drugs, Drug/Device Products
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
Need a specific report? 1000+ reports available
Buy Reports